The challenge for modern longevity medicine lies in the lack of a universal metric. A 2025 double-blind, placebo-controlled trial led by Corley et al. demonstrated that semaglutide could reduce PhenoAge by 4.9 years and improve the DunedinPACE aging metric by 9%. Yet, in the same patient populations, VO₂ max—the gold standard for cardiorespiratory fitness—remained stubbornly flat. This divergence suggests that interventions may target specific biological dimensions while leaving others entirely untouched, complicating how clinicians define a successful outcome.

This discrepancy creates a significant diagnostic hurdle. A 2025 review from the University of Virginia School of Medicine highlighted that even with weight loss, GLP-1 receptor agonists do not necessarily boost VO₂ max, a result that defies conventional fitness expectations. Consequently, relying on a single biomarker often leads to an incomplete picture of patient health. While epigenetic clocks like GrimAge and PhenoAge have proven sensitive enough to capture intervention effects in controlled settings, they cannot substitute for physical performance metrics.

For the broader category of wellness peptides—such as BPC-157 or CJC-1295—the clinical reality is even more opaque. A 2026 systematic review in Frontiers in Aging confirmed a total absence of high-quality, long-term human trials for these compounds. Without standardized trial data, the link between these popular off-label treatments and actual biological age reversal remains speculative. For patients and practitioners alike, the current evidence suggests that tracking a combination of epigenetic and physical markers is the only way to navigate the gap between emerging research and clinical practice.